Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5%
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Subscribe To Our Newsletter & Stay Updated
